Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Portola Pharmaceuticals

Request full access

Therapeutics for acute and chronic cardiovascular, and autoimmune and inflammatory diseases

South San Francisco, United StatesFounded 2003Biotech & Life Sciences

About Portola Pharmaceuticals

Portola Pharmaceuticals, Inc. operated as a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing treatments in thrombosis and other hematologic diseases. The company was established on September 2, 2003, by co-founders Charles J. Homcy, M.D., and David R. Philips. Homcy served as the company's president and CEO until 2010 before transitioning to the Board of Directors. The company's name was inspired by Gaspar de Portolà, the first European to see the San Francisco Bay. A significant milestone was its initial public offering (IPO) on NASDAQ in May 2013. In May 2020, Alexion Pharmaceuticals announced its intention to acquire Portola for $1.41 billion, a deal that was completed in July 2020.

The company's business model revolved around the research, development, and commercialization of novel drugs for patients with limited treatment options. Portola's revenue was generated through the sale of its approved products and through collaboration agreements with other pharmaceutical giants like Bristol-Myers Squibb, Pfizer, and Daiichi Sankyo. These agreements often involved cash payments and development support, while Portola typically retained commercial rights. The company also entered into royalty agreements, such as a $150 million deal with HealthCare Royalty Partners for Andexxa, to secure non-dilutive funding for commercialization and further development.

Portola developed and brought to market two key products. The first, Andexxa [coagulation factor Xa (recombinant), inactivated-zhzo], is the first and only FDA-approved antidote for reversing the anticoagulant effects of Factor Xa inhibitors rivaroxaban and apixaban in patients experiencing life-threatening or uncontrolled bleeding. Approved by the FDA in May 2018 under an Accelerated Approval pathway, Andexxa addresses a critical need in emergency hospital settings. The second approved medicine, Bevyxxa (betrixaban), is an oral, once-daily Factor Xa inhibitor for preventing venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness. The company was also advancing cerdulatinib, a Syk/JAK inhibitor being investigated for the treatment of hematologic cancers.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2013
Employees
52
Open positions
None listed
Dealroom signal
29.2/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Oncology, Cardiology and cardiovascular, Verified Unicorns and $1B Exits, Post IPO $1B, Biotech and Pharma, DT and LS, science-based
Client focus
B2B

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing May 2020 $1.4B $1.4B Alexion Pharmaceuticals ↗
POST IPO EQUITYOther financing Aug 2019 $259M — Undisclosed ↗
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

Portola Pharmaceuticals website traffic

Latest recorded traffic for Portola Pharmaceuticals is 210 monthly website visits, down 78.4% over the last three months. Portola Pharmaceuticals's team declined 46.9% over the past year.

Latest monthly visits210 3-month web change-78.4% 1-year team growth-46.9%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Portola Pharmaceuticals in the South San Francisco ecosystem

Live from Dealroom

The Portola Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

22 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A7 investors entered at this stage

  • Prospect Venture Partners
  • Sutter Hill Ventures
  • MPM BioImpact
  • Frazier Healthcare Partners
  • Abingworth
  • Advanced Technology Ventures
  • Alta Partners

Series B and later14 investors entered at this stage

  • Brookside Capital
  • AllianceBernstein
  • Ontario Teachers’ Pension Plan
  • Goldman Sachs
  • T. Rowe Price
  • D.E. Shaw Group
  • Janus Capital Group
  • Pac-Link
  • IBT Management Corporation
  • Adage Capital
  • Temasek
  • Eastern Capital
  • HealthCare Royalty
  • Athyrium Capital Management

Other known investors1 additional known investor

  • Alexion Pharmaceuticals
Team profiled 25 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States95.8%
🇬🇧 United Kingdom4.2%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Portola Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Portola Pharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.